Literature DB >> 30308314

Naturally split intein Npu DnaE mediated rapid generation of bispecific IgG antibodies.

Lei Han1, Huifang Zong2, Yuexian Zhou2, Zhidi Pan2, Jie Chen2, Kai Ding2, Yueqing Xie3, Hua Jiang3, Baohong Zhang2, Huili Lu2, John Gilly4, Jianwei Zhu5.   

Abstract

High product purity, preserving natural IgG architecture, and excellent production efficiency are highly desirable in bispecific antibody manufacturing. We have reported a platform called Bispecific Antibody by Protein Trans-Splicing (BAPTS) to synthesize BsAbs with natural human IgG structure and no chain mispairing. In the method, two antibody fragments carrying different target-specificities are separately expressed in mammalian cells and subsequently fused to form BsAbs by utilizing the trans-splicing property of the split intein Npu DnaE. The hinge region of antibody, a region with less functional impact, is selected for conjugating the two fragments. The method involves the following steps: (i) constructing five plasmids coding antibody components; (ii) separately expressing and purifying two antibody fragments A and B. Fragment A contains one Fab, "Knobs-into-Holes" mutations in the CH3 domain and NPU DnaEC. Fragment B contains another Fab and NPU DnaEN; (iii) mixing of fragments A and B under permissive reducing conditions in vitro to enable trans-splicing reaction; (iv) removing the reductant to allow re-oxidation of disulfide bonds; (v) isolating BsAb product from unreacted precursors by affinity chromatography. The method allows correct assembly of two heavy and two light chains to form bispecific IgG antibodies in natural structure with no synthetic linkers. No chain mispairing was observed in the product by UPLC-MASS. In addition, the observed kinetics and low reaction activation energy confirmed that the trans-splicing is thermodynamically favored reaction. The BAPTS technology is feasible for industrial applications.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bispecific antibody; Npu DnaE; Protein engineering; Split intein; Trans-splicing reaction

Mesh:

Substances:

Year:  2018        PMID: 30308314     DOI: 10.1016/j.ymeth.2018.10.001

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  7 in total

1.  Kinetics study of the natural split Npu DnaE intein in the generation of bispecific IgG antibodies.

Authors:  Huifang Zong; Lei Han; Jie Chen; Zhidi Pan; Lei Wang; Rui Sun; Kai Ding; Yueqing Xie; Hua Jiang; Huili Lu; John Gilly; Baohong Zhang; Jianwei Zhu
Journal:  Appl Microbiol Biotechnol       Date:  2021-12-09       Impact factor: 4.813

2.  Production of IgG1-based bispecific antibody without extra cysteine residue via intein-mediated protein trans-splicing.

Authors:  Hiroki Akiba; Tomoko Ise; Satoshi Nagata; Haruhiko Kamada; Hiroaki Ohno; Kouhei Tsumoto
Journal:  Sci Rep       Date:  2021-09-30       Impact factor: 4.379

3.  IgG-like Bispecific Antibody CD3×EpCAM Generated by Split Intein Against Colorectal Cancer.

Authors:  Lei Wang; Yu Qiao; Huifang Zong; Lei Han; Yong Ke; ZhiDi Pan; Jie Chen; Jun Lu; Jinyao Li; Tianlei Ying; Baohong Zhang; Jianwei Zhu
Journal:  Front Pharmacol       Date:  2022-02-23       Impact factor: 5.810

4.  The Generation of Dual-Targeting Fusion Protein PD-L1/CD47 for the Inhibition of Triple-Negative Breast Cancer.

Authors:  Yanlin Bian; Tong Lin; Tanja Jakos; Xiaodong Xiao; Jianwei Zhu
Journal:  Biomedicines       Date:  2022-07-30

5.  Intein mediated high throughput screening for bispecific antibodies.

Authors:  Tim Hofmann; Johannes Schmidt; Elke Ciesielski; Stefan Becker; Thomas Rysiok; Mark Schütte; Lars Toleikis; Harald Kolmar; Achim Doerner
Journal:  MAbs       Date:  2020 Jan-Dec       Impact factor: 5.857

6.  A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer.

Authors:  Yuexian Zhou; Huifang Zong; Lei Han; Yueqing Xie; Hua Jiang; John Gilly; Baohong Zhang; Huili Lu; Jie Chen; Rui Sun; Zhidi Pan; Jianwei Zhu
Journal:  J Exp Clin Cancer Res       Date:  2020-05-12

Review 7.  Toward Drug-Like Multispecific Antibodies by Design.

Authors:  Manali S Sawant; Craig N Streu; Lina Wu; Peter M Tessier
Journal:  Int J Mol Sci       Date:  2020-10-12       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.